Anja Rockstroh
Overview
Explore the profile of Anja Rockstroh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
402
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Tousignant K, Rockstroh A, Fard A, Lehman M, Wang C, McPherson S, et al.
Mol Cancer Res
. 2019 Feb;
17(5):1166-1179.
PMID: 30808729
lipogenesis is a well-described androgen receptor (AR)-regulated metabolic pathway that supports prostate cancer tumor growth by providing fuel, membrane material, and steroid hormone precursor. In contrast, our current understanding of...
12.
Stylianou N, Lehman M, Wang C, Fard A, Rockstroh A, Fazli L, et al.
Oncogene
. 2018 Dec;
38(13):2436.
PMID: 30510231
Following the publication of the above article, the authors noted an error in Figure 4, panel B. The colours of the localized and mCRPC samples were accidentally switched. The authors...
13.
Loessner D, Rockstroh A, Shokoohmand A, Holzapfel B, Wagner F, Baldwin J, et al.
Biomaterials
. 2018 Nov;
190-191:63-75.
PMID: 30396040
Peritoneal invasion through the mesothelial cell layer is a hallmark of ovarian cancer metastasis. Using tissue engineering technologies, we recreated an ovarian tumor microenvironment replicating this aspect of disease progression....
14.
Wang P, Magdolen V, Seidl C, Dorn J, Drecoll E, Kotzsch M, et al.
Br J Cancer
. 2018 Oct;
119(7):1-9.
PMID: 30287916
Background: Tissue kallikrein-related peptidases 4, 5, 6 and 7 (KLK4-7) strongly increase the malignancy of ovarian cancer cells. Deciphering their downstream effectors, we aimed at finding new potential prognostic biomarkers...
15.
Stylianou N, Lehman M, Wang C, Fard A, Rockstroh A, Fazli L, et al.
Oncogene
. 2018 Sep;
38(7):913-934.
PMID: 30194451
The propensity of cancer cells to transition between epithelial and mesenchymal phenotypic states via the epithelial-mesenchymal transition (EMT) program can regulate metastatic processes, cancer progression, and treatment resistance. Transcriptional investigations...
16.
Soekmadji C, Rockstroh A, Ramm G, Nelson C, Russell P
Proteomics
. 2017 Nov;
17(23-24).
PMID: 29105980
Current treatments for advanced prostate cancer focus on inhibition of the androgen receptor (AR) by androgen deprivation therapy (ADT). However, complex interactions mediated by tumor suppressors, oncogenes, aberrations of AR...
17.
Levrier C, Rockstroh A, Gabrielli B, Kavallaris M, Lehman M, Davis R, et al.
Cell Cycle
. 2017 Jul;
17(5):652-668.
PMID: 28749250
We report for the first time the mechanism of action of the natural product thalicthuberine (TH) in prostate and cervical cancer cells. TH induced a strong accumulation of LNCaP cells...
18.
Levrier C, Sadowski M, Rockstroh A, Gabrielli B, Kavallaris M, Lehman M, et al.
Mol Cancer Ther
. 2016 Oct;
16(1):3-15.
PMID: 27760837
The lack of a cure for metastatic castrate-resistant prostate cancer (mCRPC) highlights the urgent need for more efficient drugs to fight this disease. Here, we report the mechanism of action...
19.
Liberio M, Sadowski M, Davis R, Rockstroh A, Vasireddy R, Lehman M, et al.
Oncotarget
. 2016 Jan;
6(41):43944-63.
PMID: 26733491
As part of an anti-cancer natural product drug discovery program, we recently identified eusynstyelamide B (EB), which displayed cytotoxicity against MDA-MB-231 breast cancer cells (IC50 = 5 μM) and induced...
20.
Tevz G, McGrath S, Demeter R, Magrini V, Jeet V, Rockstroh A, et al.
Mol Cell Endocrinol
. 2015 Oct;
420:159-68.
PMID: 26499396
Simultaneous expression of highly homologous RLN1 and RLN2 genes in prostate impairs their accurate delineation. We used PacBio SMRT sequencing and RNA-Seq in LNCaP cells in order to dissect the...